Bank Of New York Mellon Corp Cabaletta Bio, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$7.08 - $12.62 $182,246 - $324,851	25,741 New	25,741 $213 Million
Q4 2022 Feb 14, 2023	BUY	$0.64 - $9.3 $16,474 - $239,391	25,741 New	25,741 $238,000
Q2 2022 Aug 15, 2022	SELL	$0.99 - $2.11 $3,813 - $8,127	-3,852 Reduced 16.99%	18,822 $20,000
Q1 2022 May 11, 2022	BUY	$1.68 - $3.92 $20,796 - $48,525	12,379 Added 120.24%	22,674 $46,000
Q2 2021 Aug 11, 2021	SELL	$7.2 - $11.73 $291,132 - $474,302	-40,435 Reduced 79.71%	10,295 $88,000
Q1 2021 May 13, 2021	BUY	$10.39 - $14.53 $12,177 - $17,029	1,172 Added 2.36%	50,730 $563,000
Q4 2020 Feb 09, 2021	SELL	$9.81 - $15.8 $19,119 - $30,794	-1,949 Reduced 3.78%	49,558 $618,000
Q3 2020 Nov 12, 2020	BUY	$9.71 - $14.41 $74,679 - $110,827	7,691 Added 17.55%	51,507 $558,000
Q2 2020 Aug 12, 2020	BUY	$6.39 - $11.28 $145,468 - $256,789	22,765 Added 108.14%	43,816 $488,000
Q1 2020 May 06, 2020	BUY	$6.0 - $18.67 $50,940 - $158,508	8,490 Added 67.59%	21,051 $153,000
Q4 2019 Feb 14, 2020	BUY	$7.88 - $17.71 $98,980 - $222,455	12,561 New	12,561 $175,000

126

47.9M

202K

110K

Ticker CABA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,014,000
Market Cap $66.4M
Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.